Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Sera Prognostics, Inc.NASDAQ: SERA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to -200.0%

Gross margin was -200.0% in Q1 FY2026, down 194.7 pp from a year earlier. On a trailing-twelve-month basis it was -191.2%, down 199.9 pp year over year. Over 3 fiscal years it narrowed by 130.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-200.0%+120.0 pp QoQ
Last fiscal yearDec 2025
-102.5%-96.0 pp YoY
LTMMar 2026
-191.2%-199.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-194.7 pp——
1 year-96.0 pp——
3 years-130.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-102.5%
Year-over-year change
-96.0pp

Gross Margin vs competitors

How SERA compares with its peers on the latest reported figures

  • SERA's LTM Mar 2026 gross margin of -191.2% is the lowest of the 6 companies compared; the peer median is 12.4%.
  • Its year-over-year change of -199.9 pp is the lowest of 5, against a peer median of +4.4 pp.
  • Over three fiscal years its change of -130.5 pp compares with a peer median of +41.6 pp.
SERA Competitors Peer median
Gross Margin for SERA and competitors
Company Period LTM level YoY 3-year change
SRZNSurrozen, Inc.LTM Mar 202699.1% +2.4 pp+10.7 pp
APYXApyx Medical CorporationLTM Mar 202632.3% -19.3 pp-29.4 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
STSSSkyAI, Inc.LTM Mar 2026-106.6% ——
SERASera Prognostics, Inc.LTM Mar 2026-191.2% -199.9 pp-130.5 pp
HURATuHURA Biosciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
ONCYOncolytics Biotech Inc.FY2025— ——
Peer median (excluding SERA) 12.4%+4.4 pp+41.6 pp

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue82K268K306K77K81K
Cost of Revenue37K193K210K82K164K
Gross Profit45K75K96K(5K)(83K)
Gross Margin54.9%28.0%31.4%-6.5%-102.5%
Research & Development11.02M14.24M15.23M14.73M13.17M
Selling, General & Admin24.42M31.48M24.69M21.9M23.25M
Operating Expenses35.44M45.73M39.92M36.63M36.42M
Depreciation & Amortization659K756K900K833K940K
EBITDA(33.6M)(43.37M)(35.29M)(32.04M)(30.98M)
EBITDA Margin-40980.5%-16182.5%-11531.7%-41606.5%-38245.7%
Operating Income(35.4M)(45.65M)(39.82M)(36.64M)(36.5M)
Operating Margin-43164.6%-17034.3%-13013.4%-47577.9%-45066.7%
Interest Income145K456K1.64M2.75M4.59M
Interest Expense746K61K55K28K9K
Other Income / Expenses386K1.47M3.58M3.74M4.58M
Income Before Tax(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Pre-Tax Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
Income Tax Expense00000
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Net Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
EPS (Basic)(1.18)(1.43)(1.16)(0.99)(0.67)
EPS (Diluted)(1.18)(1.43)(1.16)(0.99)(0.67)
Weighted Avg Shares30.77M30.94M31.2M33.16M47.66M
Weighted Avg Shares (Diluted)30.77M30.94M31.2M33.16M47.66M

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.